Research announcement · Alliance for Clinical Trials in Oncology · 2026-08-13

Investigators found no clear improvement in the time before advanced bowel cancer progressed when patients received a higher vitamin D3 dose alongside treatment.

The SOLARIS study followed up a possible benefit seen in the smaller SUNSHINE trial. It enrolled 455 people starting treatment for metastatic bowel cancer. They received standard cancer therapy and were randomly assigned either a higher or a standard dose of vitamin D3.

The median time before progression or death was 11.8 months in the higher-dose group and 10.3 months in the standard-dose group. The difference was compatible with chance. Overall survival was also similar between the groups.

Both groups received chemotherapy together with bevacizumab. The trial used two standard chemotherapy regimens and kept the type of chemotherapy separate from the random assignment to the two vitamin D doses.